Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1651 to 1665 of 8939 results

  1. Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments (TA927)

    Evidence-based recommendations on glofitamab (Columvi) for treating relapsed or refractory diffuse large B-cell lymphoma in adults after 2 or more systemic treatments.

    Technology appraisal guidance
    Published
    17 October 2023
    View recommendations

    Sections for TA927

  2. Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and under (TA975)

    Evidence-based recommendations on tisagenlecleucel (Kymriah) for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and under.

    Technology appraisal guidance
    Published
    15 May 2024
    View recommendations

    Sections for TA975

  3. Burosumab for treating X-linked hypophosphataemia in adults (TA993)

    Evidence-based recommendations on burosumab (Crysvita) for treating X-linked hypophosphataemia in adults.

    Technology appraisal guidance
    Published
    7 August 2024
    View recommendations

    Sections for TA993

  4. Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma (TA997)

    Evidence-based recommendations on pembrolizumab (Keytruda) with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma in adults.

    Technology appraisal guidance
    Published
    29 August 2024
    View recommendations

    Sections for TA997

  5. Transvenous embolisation for treating cerebrospinal fluid-venous fistula associated with spontaneous intracranial hypotension

    In development Reference number: GID-IPG10318 Expected publication date:  25 March 2026

    Interventional procedures guidance
    In development

  6. Suspected Cancer: recognition and referral (update)

    In development Reference number: GID-NG10443 Expected publication date:  25 March 2026

    NICE guideline
    In development

  7. Percutaneous insertion of a catheter-based left ventricular microaxial flow pump for cardiogenic shock

    In development Reference number: GID-IPG10404 Expected publication date:  25 March 2026

    Interventional procedures guidance
    In development

  8. Surgical insertion of a catheter-based left ventricular microaxial flow pump for cardiogenic shock

    In development Reference number: GID-IPG10461 Expected publication date:  25 March 2026

    Interventional procedures guidance
    In development

  9. Dapsone for treating COVID-19 in people 40 years and over with high-risk comorbidity and people 70 years and over [TSID11892]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  10. Subcutaneous ocrelizumab for treating primary progressive or relapsing multiple sclerosis [TSID11895]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  11. Subcutaneous C1-esterase inhibitor for preventing recurrent attacks of hereditary angioedema in people 12 years and over [TSID11891]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  12. Avtozma (tocilizumab biosimilar) for treating moderate to severe rheumatoid arthritis in people aged 18 to 75 [TSID11848]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  13. Subcutaneous ravulizumab for treating paroxysmal nocturnal haemoglobinuria or atypical haemolytic uraemic syndrome [TSID11820]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  14. CT-P39 (omalizumab biosimilar) for previously treated chronic spontaneous urticaria [TSID11832]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  15. Semaglutide for treating obesity-related heart failure with preserved ejection fraction [TSID11788]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation